Supplementary Table 1. (A) S100β Validation set (n=76 ER-positive and ER-negative patients). (B) S100β Validation set (n=59 ER-positive patients). Association.

Slides:

Advertisements

Similar presentations

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Advertisements

Treatment of Relapsed Osteosarcoma After Contemporary Therapy: The Memorial Sloan-Kettering Experience Chou AJ, Merola PR, Vyas Y, Wexler L, Gorlick R,

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

2 years later, she noticed multiple cm

SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,

Acinic Cell Carcinoma of the Parotid Gland Metastatic to the Epidermis of the Back Pilcher R. Davidson MJC. Department of Oral and Maxillofacial Surgery,

Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.

SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME

PHASE I TRIAL OF CONCURRENT CHEMORADIOTHERAPY USING DOXIFLURIDINE AND PACLITAXEL IN ADVANCED BREAST CANCER H.Hirowatari 1, K. Karasawa 1,2,

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.

Supplementary Table 1: Clinicopathologic characteristics of 100 patients with invasive breast cancer Clinical characteristicsNumber of cases (%) Median.

JOURNAL OF CLINICAL ONCOLOGY 2012; vol 30 Thomas Bachelot, Ce´line Bourgier, Claire Cropet, Isabelle Ray-Coquard, Jean-Marc Ferrero, Gilles Freyer, Sophie.

Case Discussion. Case #1 64 year-old postmenopausal, no PMHx Routine MMG: 2cm nodule in RUQ, with microcalcifications Biopsy: IDC grade 2 with areas of.

Breast Surgery in Delhi Breast Cancer Epidemiology Halsted Theory Radical Mastectomy Fisher Theory Modified Radical Mastectomy Goals of Breast Conservation.

BREAST CANCER Anterpreet Neki, MD , MS

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome Gaia Griguolo DiSCOG-University.

Challenges for the treatment of breast cancer

Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome WILLIAM M.

Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon

Number of brain metastasis

Training Set Clinicopathological parameters of the training set

Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,

ABRAMYO Phase I-II study of weekly nab paclitaxel in combination with liposomal encapsulated doxorubicin in patients with HER2 negative MBC Alessandra.

Underwriting Breast Cancer

Ari Brooks, MD Cancer Surgeon, Big Data End User

Prognostic significance of tumor subtypes in male breast cancer:

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Operative Approach and

RCR breast radiotherapy consensus guidelines

Dr Amit Gupta Associate Professor Dept Of Surgery

Principles of oncology

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Fig 1A. Patient enrollment flow chart

羅喬，王明暘，郭文宏，黃俊升台大醫院外科部一般外科乳房外科

BREAST CANCER A full classification includes histopathological type, grade, stage (TNM), receptor status, and the presence or absence of genes as determined.

Johns Hopkins Hospital Cancer Registry

Picture 3. Higher grade tumors are more frequently Ki67 positive

THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.

Prognosis of younger patients in non-small cell lung cancer

Table (1):Relation between lymph node and molecular subtypes.

Erica V. Bloomquist, MD Heather Wright, MD

SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,

MAP-tau expression in the Yale University Cohort

South London Genomic Medicine Centre Cancer Cases Dr Alison May Berner ST4 Academic Clinical Fellow in Medical Oncology 4th June 2018.

Table 1 Case # Age at primary Biopsy (year) Age at metastasis

Apollo Gleneagles Hospitals,

Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.

Dr T P E Wells 13 July 2018 Breast SSG Bath

Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome WILLIAM M.

Treatment Overview: The Multidisciplinary Team

Handling and Evaluation of Breast Cancer Biopsy

Patients who have received chemotherapy (n=60)

Disease-specific survival

Volume 148, Issue 1, Pages (January 2018)

ORGANISM: An organism has several organ systems that work together.

Figure 1 KCTD16 antibodies are associated with an underlying tumour

Supplementary Table S1. H-scores of ICAM-1, VCAM-1 and IP-10 expression in tumors of melanoma patients before and after ipilimumab or Ipi-Bev treatment.

FMRP is highly expressed in human breast cancer and distal metastasis FMRP expression on human TMAs containing normal and multi‐tumour tissues. FMRP is.

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR

20-Year Risks of Breast-Cancer Recurrence

Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:

Figure 1. CONSORT diagram.

NSCLC: Staging and TNM classification

Myc succeeds Akt activation and is required for growth of metastatic prostate cancer. Myc succeeds Akt activation and is required for growth of metastatic.

Genomic determinants of response to cytotoxic chemotherapy.

Authors: Sunil Verma Date posted: December 22, 2008

Detection of E-cadherin fragments in human prostate cancer metastases.

Presentation transcript:

Supplementary Table 1. (A) S100β Validation set (n=76 ER-positive and ER-negative patients). (B) S100β Validation set (n=59 ER-positive patients). Association of S100β status with clinicopathological variables and disease recurrence using Fisher exact test. A B S100β ≥0.13 S100β <0.13 P value n = 6 (7.89%) n = 70 (92.11%) Age ≥55 2 (33.33%) 30 (42.86%) 1.0 <55 4 (66.67%) 40 (57.14%) ER +ve 5 (83.33%) 54 (77.14%) -ve 1 (16.67%) 16 (22.86%) PR 6 (100%) 55 (79.71%) 0.586 - 14 (20.29%) Her2 3 (50%) 10 (14.29%) 0.059 60 (85.71%) Grade ≥ 3 0.089 < 3 Size ≥ 20 mm 47 (68.12%) 0.171 <20 mm 22 (31.88%) Node 35 (53.03%) 0.681 31 (46.97%) Recurrence 14 (20%) 0.025 (r= +0.296) 56 (80%) S100β ≥0.13 S100β <0.13 P value n = 5 (8.47%) n = 54 (91.53%) Age ≥55 1 (20%) 21 (38.89%) 0.641 <55 4 (80%) 33 (61.11%) PR +ve 5 (100%) 51 (96.23%) 1.00 -ve - 2 (3.77%) Her2 3 (60%) 5 (9.26%) 0.015 2 (40%) 49 (90.74%) Grade ≥ 3 18 (33.33%) 0.059 < 3 36 (66.67%) Size ≥ 20 mm 5(100%) 37 (69.81%) 0.309 <20 mm 16 (30.19%) Node 30 (57.69%) 22 (42.31%) Recurrence 8 (14.81%) 0.04 (r=+0.3231) 46 (85.19%) *Median age was 51.30 years. †Median follow-up time was 70.56 months. *Median age was 52.15 years. †Median follow-up time was 70.7 months.

Supplementary Table 2. Pre-Operative and Post-operative S100β serum levels in 55 ER-positive patients. Association of S100β status with clinicopathological variables using Fisher exact test. S100β ≥0.13 S100β <0.13 P value n = 6 (10.91%) n = 49 (89.09%) Age ≥55 2 (33.33%) 18 (36.73%) 0.204 <55 4 (66.67%) 31 (63.27%) PR +ve 40 (81.63%) 0.588 -ve 9 (18.37%) Her2 0 (0%) 6 (13.04%) 1.0 6 (100%) 40 (86.96%) Node 3 (75%) 21 (47.73%) 0.609 1 (25%) 23 (52.27%) Grade ≥Grade 3 1 (16.67%) 9 (19.15%) <Grade 3 5 (83.33%) 38 (80.85%) Size ≥20 mm 7 (100%) 32 (100%) *Median age was 50.25 years. †Post-operative bloods were taken <12 month following operation (Median time from operation is 1.8 months).

Supplementary Table 3. S100β tissue expression in matched primary and metastatic tissue from ER-positive patients. Primary Histology Metastasis Histology Site of Metastasis ER PR Her2 S100β Patient 1 + - ++ +++ Bone Patient 2 Lung Patient 3 Un Patient 4 --

Supplementary Table 4. Patient details from ex-plant study Supplementary Table 4. Patient details from ex-plant study. Ex-plant endocrine resistant tumour tissue (n=2) was treated with AI therapy (Letrozole) in the presence and absence of dasatinib. Treatmnet Primary Histology Time to recurrence Metastatic Histology Patient 1 AI ER + PR- HER2+ 26 Patient 2 PR+ HER2- 28